| Market Cap | 12.77M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -14.17M | Forward P/E | 0.93 | EPS next Y | - | 50D Avg Chg | -8.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -52.00% |
| Dividend | N/A | Price/Book | 0.39 | EPS next 5Y | 41.70% | 52W High Chg | -91.00% |
| Recommedations | 2.00 | Quick Ratio | 3.59 | Shares Outstanding | 1.61M | 52W Low Chg | 8.00% |
| Insider Own | 53.46% | ROA | -21.89% | Shares Float | 896.02K | Beta | 1.34 |
| Inst Own | 4.63% | ROE | -67.28% | Shares Shorted/Prior | 19.20K/10.60K | Price | 7.96 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 33,600 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 3,227 | Change | -1.73% |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SMISEK JEFFERY A | Director Director | Nov 22 | Sell | 3.64 | 1,470 | 5,351 | 6,642 | 11/27/23 |